Perrigo Company Plc - Form 8-K Summary
Business Context and Reporting Period
Date of Report: November 6, 2014
Company: Perrigo Company Plc
Event: Entry into a Material Definitive Agreement (Share Purchase Agreement) to acquire Omega Pharma Invest NV.
Perrigo entered into an agreement to purchase 685,348,257 shares of Omega Pharma Invest NV, representing 95.77% of its issued and outstanding share capital. The transaction is expected to close during the third quarter of fiscal 2015, subject to regulatory approvals and other closing conditions.
Key Financial Metrics and Transaction Structure
Acquisition Consideration:
- Cash Consideration: EUR 1,845,983,131.
- Non-Cash Consideration: 5,397,711 shares of Perrigo Company Plc issued to seller Alychlo NV.
- Interest Adjustment: Consideration increases by interest on EUR 2.48 billion from September 30, 2014, to the completion date at a starting rate of 5%.
Assumed Indebtedness: Perrigo will assume or repay/redeem Omega's outstanding debt, including:
- EUR 135,043,889 of 5.1045% senior notes due 2023.
- USD 20,000,000 (approx. EUR 16,247,000) of 6.19% senior notes due 2016.
- EUR 300,000,000 of 5.125% retail bonds due 2017.
- EUR 180,000,000 of 4.500% retail bonds due 2017.
- EUR 120,000,000 of 5.000% retail bonds due 2019.
- Approximately EUR 390,000,000 under credit and overdraft facilities.
Financing Commitments: JPMorgan Chase Bank, N.A. and Barclays Bank PLC have committed to:
- Up to EUR 1.75 billion under a 364-day senior unsecured bridge loan facility.
- Amendments or new facilities for term loans up to USD 300 million and EUR 800 million.
- Amendments or new facilities for revolving credit up to USD 1 billion.
Liquidity and Security: Sellers' indemnification obligations are secured by a 15-month escrow of cash and shares and/or guarantees totaling up to EUR 248.0 million.
Material Changes and Conditions
This filing represents a material change in the Company's capital structure and business scope due to the proposed acquisition. The transaction is conditioned upon:
- Antitrust approval (including potential divestitures).
- Accuracy of representations and warranties.
- Compliance with covenants.
- No material adverse effect on Omega.
If closing conditions are not met by August 6, 2015, either party may terminate the agreement. If Perrigo fails to use best efforts to satisfy antitrust conditions, the Sellers may terminate and receive a EUR 100,000,000 break fee.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to use best efforts to satisfy antitrust conditions. The transaction is expected to be completed in Q3 fiscal 2015.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain required antitrust approvals could terminate the deal or require divestitures.
- Financing Risk: Access to financing on reasonable terms is not guaranteed.
- Integration Risk: Uncertainty regarding the ability to recognize anticipated synergies.
- Industry Risk: Product liability claims and market demand fluctuations in the pharmaceutical industry.
- Forward-Looking Statements: Actual results may differ materially from projections due to known and unknown risks.
Unregistered Sales: The non-cash consideration shares are being issued in a private placement exempt from registration under Section 4(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date and whether the August 6, 2015, termination deadline is met.
- Confirm receipt of all necessary antitrust and regulatory approvals.
- Monitor the execution of the definitive financing documentation for the bridge and term loan facilities.
- Review the final amount of interest accrued on the EUR 2.48 billion base amount at closing.
- Assess the impact of assumed debt on the Company's leverage ratios and liquidity position post-closing.
- Check for any required divestitures mandated by antitrust authorities.